By Billy Candra 
Cambridge researchers have unveiled a groundbreaking new treatment approach that has demonstrably improved survival rates for patients battling aggressive, inherited forms of breast cancer, achieving a remarkable 100% survival rate over a critical three-year period post-surgery in a recent trial. This significant advancement, detailed today in the prestigious journal Nature Communications, presents a powerful new weapon against early-stage breast cancers driven by inherited BRCA1 and BRCA2 gene mutations, potentially marking it as the most effective treatment strategy to date for these challenging diagnoses.
The Innovative Approach: Timing is Key
The Partner trial, a pivotal study led by experts from Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust, and the University of Cambridge, introduced a novel sequence in patient care. Instead of the standard approach of chemotherapy and immunotherapy followed by surgery, the trial integrated a targeted cancer drug, olaparib, before surgical intervention. Crucially, the trial also illuminated the profound benefits of meticulously timing these treatments. Patients in the intervention arm received chemotherapy, followed by a deliberate 48-hour "gap," before commencing treatment with olaparib. This sequential administration, researchers believe, allows a patient’s bone marrow sufficient time to recover from the cytotoxic effects of chemotherapy, while simultaneously leaving the aggressive tumour cells susceptible and vulnerable to the targeted action of olaparib.
The results from this innovative regimen are compelling. Of the 39 patients who underwent this specific treatment sequence of chemotherapy followed by olaparib with the strategic 48-hour interval, an extraordinary 100% survived the critical three-year period following surgery. Only a single patient in this cohort experienced a relapse within this timeframe. In stark contrast, the control arm of the study, comprising 45 patients who received standard chemotherapy only, recorded a survival rate of 88% over the same three-year post-surgery period. A concerning nine patients in the control group relapsed, and tragically, six of these patients succumbed to their disease.
Understanding BRCA-Mutated Cancers
Breast cancers associated with faulty copies of the BRCA1 and BRCA2 genes are notoriously aggressive and present unique therapeutic challenges. These genes are vital components of the body’s DNA repair machinery, and mutations in them can lead to an increased lifetime risk of developing several cancers, most notably breast and ovarian cancers. While BRCA mutations account for approximately 5-10% of all breast cancers, they are often linked to earlier onset and more aggressive tumour characteristics, including triple-negative breast cancer, which is particularly difficult to treat. For women carrying a BRCA1 mutation, the lifetime risk of developing breast cancer can be as high as 40-85%, and for BRCA2 carriers, it ranges from 40-60%. These statistics underscore the urgent need for more effective treatments for this specific patient population.
Public awareness of BRCA mutations dramatically increased in 2013 when actress Angelina Jolie, a carrier of the BRCA1 mutation, openly discussed her preventative double mastectomy. Her decision highlighted the hereditary nature of these cancers and the proactive measures individuals can take, but it also cast a spotlight on the inherent anxieties and difficult choices faced by carriers. The Partner trial’s findings offer a beacon of hope for those diagnosed with these challenging, inherited forms of the disease.
Olaparib: A Targeted Therapy with Expanded Potential
Olaparib is a targeted cancer drug already approved and available on the NHS. It belongs to a class of drugs known as PARP inhibitors (poly ADP-ribose polymerase inhibitors). PARP proteins are involved in DNA repair, and by inhibiting them, olaparib effectively prevents cancer cells with compromised DNA repair mechanisms (like those with BRCA mutations) from repairing their own DNA damage, leading to cell death. Currently, olaparib is typically offered to patients post-surgery for a duration of 12 months.
The Partner trial’s innovative application of olaparib pre-surgery, and for a significantly shorter duration of just 12 weeks, not only yielded superior clinical outcomes but also presents potential cost-saving benefits for the NHS. This shorter, pre-surgical course could reduce the overall financial burden of treatment and potentially lessen the side effects associated with prolonged drug use, offering a less toxic yet more effective treatment pathway for patients.
A Patient’s Journey: Hope and Resilience
Among the patients whose lives have been positively impacted by this trial is Jackie Van Bochoven, 59, from South Cambridgeshire. Diagnosed in February 2019 with a small but aggressive tumour, Jackie’s initial reaction was one of profound shock and fear. "When I had the diagnosis, I was completely shocked and numb," she recounted, reflecting on the immediate thoughts that turned to her children and her own family history of breast cancer, including her mother and sister. "I was pretty worried."
Today, six years on, Jackie is not only well but cancer-free, a testament to the success of the treatment she received through the trial. "I’m back at work, enjoying life and spending time with my family," she shared, her voice imbued with gratitude. "When you’ve had cancer, I think you look at life differently and every day is a bonus." Her story embodies the profound impact such medical advancements have on individual lives, transforming fear into renewed hope and vitality.
Broader Implications and Future Directions
The potential implications of the Partner trial extend far beyond breast cancer. The findings suggest that this precisely timed treatment strategy could be applicable to other cancers caused by faulty copies of BRCA genes, including certain ovarian, prostate, and pancreatic cancers. This opens up avenues for future research and development across a spectrum of oncology.
Professor Jean Abraham, a consultant at Addenbrooke’s and the lead of the Partner trial, who also serves as Professor of Precision Breast Cancer Medicine at the University of Cambridge, articulated the profound significance of these results. "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer," Professor Abraham stated with palpable excitement. "We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers." She further revealed that the inspiration for the 48-hour gap approach emerged from a "chance conversation" with Mark O’Connor, chief scientist in Early Oncology R&D at AstraZeneca, highlighting the serendipitous yet critical role of inter-institutional dialogue in scientific discovery.
Mark O’Connor echoed this sentiment, emphasizing the trial’s dual achievements. "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule," he noted. While acknowledging the necessity for validation in larger studies, he affirmed that "the findings are incredibly exciting, and have the potential to transform outcomes for patient populations who have unmet clinical need."
A Model of Collaborative Innovation
The success of the Partner trial is a powerful testament to the efficacy of collaborative research, bringing together the NHS, academia, and industry. This model of integrated effort is precisely the vision underpinning the Cambridge Cancer Research Hospital, a specialist facility slated for construction on the Cambridge Biomedical Campus, Europe’s leading life sciences hub. This new hospital aims to consolidate clinical expertise from Addenbrooke’s Hospital with world-class scientific minds from the University of Cambridge, the Cancer Research UK Cambridge Centre, and key industry partners. The objective is to foster an environment where novel diagnostics and treatments can be rapidly developed, detecting the earliest signs of cancer and delivering truly personalized, precision medicine.
Michelle Mitchell, Chief Executive of Cancer Research UK, commended the trial’s approach, stating, "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us." She continued, "While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones." Mitchell underscored the need for further studies to confirm the safety and effectiveness of this new technique for widespread NHS adoption, but the optimism for its potential is clear.
The Road Ahead: Larger Studies and Broader Impact
The initial findings of the Partner trial represent a monumental step forward, but the scientific journey continues. Professor Abraham and her dedicated team are already meticulously planning the next phase of research. This crucial subsequent study will aim to replicate the highly encouraging results in a larger, more diverse patient cohort. Furthermore, this next phase will meticulously confirm that the Partner approach not only offers superior clinical outcomes but also provides a less toxic treatment regimen for patients and proves to be more cost-effective compared to the current standard of care.
The Partner trial was a truly collaborative endeavour, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. Its vital research was made possible through generous funding from Cancer Research UK and AstraZeneca, with additional support provided by the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT). As the scientific community looks to the future, this innovative trial stands as a powerful example of how strategic collaboration and precise scientific inquiry can lead to life-saving breakthroughs, offering renewed hope to patients and clinicians alike in the ongoing fight against cancer.